HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase...
Hence then, the article about lynk pharmaceuticals reports positive long term phase iii results for zemprocitinib in bdmards inadequate responders with moderate to severe rheumatoid arthritis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis )
Also on site :
- ‘You Can See Everything’ Ruled Ineligible for DGA Feature Prize, Will Compete Only in Documentary Category
- Disney World’s Most Talked-About Bakery Just Launched an Affordable Afternoon Hack
- The Pioneer Woman’s $22 Vintage-Style Lace Bakeware Set Is a ‘Gorgeous’ Way to Serve Holiday Favorites